Trevi Therapeutics, Inc.
TRVI
Positions held
Your positionsTRVI isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Trevi Therapeutics operates in the biotechnology sector, focusing on innovative treatments for chronic conditions, which positions it well in a growing industry.
- The company's market cap is approximately $1.88 billion, indicating significant investor interest.
- Trevi has a strong buy recommendation with a target mean price of $28.18, suggesting potential upside.
- Trevi Therapeutics has not generated any revenue, which raises concerns about its sustainability and growth prospects.
- The company reported a net income of -17.797 million in Q2 2026, continuing a trend of negative earnings over multiple quarters.
- The current score indicates a strong sell signal with a score of -16.00, reflecting bearish market sentiment.
Fundamentals
| Market cap | $1.83B | Enterprise value | $1.51B | Trailing P/E | — | Forward P/E | -22.23 |
| PEG | — | Price / book | 5.68 | Beta | 0.98 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -19.7% | ROA | -13.8% | Debt / equity | 0.00 |
| Current ratio | 37.28 | Free cash flow | -$33.28M | Analyst recommendation | strong_buy | Mean target | $28.18 |
| 52w high | $20.22 | 52w low | $9.28 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$17.8M | -$13.2M | -$8.3M | -$11.8M | -$12.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$20.5M | -$14.9M | -$10.2M | -$13.9M | -$13.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$42.8M | -$47.9M | -$29.1M | -$29.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$49.3M | -$51.5M | -$33.9M | -$29.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Top 4 Healthcare Stocks Backed by Raymond James Analysts
2026-09-25 · Trevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer Says
2026-09-17 · Trevi Therapeutics Insider Sold Shares Worth $595,806, According to a Recent SEC Filing
2026-09-05 · Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value
2026-09-03 · Trevi Therapeutics to Participate in Upcoming September Conferences
2026-08-26 · Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
2026-08-07 · Trevi Therapeutics Q2 Earnings Call Highlights
2026-08-07 · Oppenheimer Adjusts Trevi Therapeutics PT to $25 From $24, Maintains Outperform Rating
2026-08-07 · Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ...
2026-08-06 · Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-30 · Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
2026-07-28 · Trevi Therapeutics to Participate in Upcoming August Conferences
Price (daily)
Full chart · RSI · MACD · patterns